BlossomHill Therapeutics' IPO
Listed Aug 7, 2026 at $16 on Nasdaq as BLSM.
Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.
What does BlossomHill Therapeutics do?
“We are a clinical-stage biopharmaceutical company applying our intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment.”
| Fact | BlossomHill Therapeutics |
|---|---|
| Incorporated | Delaware, 2020 |
| Headquarters | San Diego, California |
| Employees | 63 full-time, as of March 31, 2026 |
| Website | bhtherapeutics.com |
What is the offering?
Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.
| Fact | BlossomHill Therapeutics |
|---|---|
| Shares offered | 9,375,000 |
| Offer price | $16 a share |
| Raised at that price | $150 million |
| Underwriters' discount | $10.5 million |
| Underwriters' option | 1,406,250 more shares |
| Underwriters | J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, and H.C. Wainwright |
| Exchange | Nasdaq Global Select Market, as BLSM |
| Shares outstanding after | 30,643,660 |
| Market cap at the offer price | $490 million |
What the filing says about its money
| Fact | BlossomHill Therapeutics |
|---|---|
| Net loss | $60.6 million, year to December 31, 2025 |
| Cash | $116 million, as of March 31, 2026 |
| Last preferred stock | Series B preferred |
| Raised before the IPO | $257 million in private financings |
What risks does BlossomHill Therapeutics name first?
- “We are a clinical-stage biopharmaceutical company with a limited operating history.”
- “Even if this offering is successful, we will require substantial additional financing to achieve our goals, which may cause dilution to our stockholders, and failure to obtain additional capital when needed, or on acceptable terms to us, could cause us to delay, limit, reduce…”
- “Our discovery and development programs are focused in part on precision medicines for patients with genetically defined cancers, which is a rapidly evolving and scientifically uncertain field, and our scientific approach, including with respect to BH-30643 and BH-30236, may never lead to marketable products.”
Every date of BlossomHill Therapeutics' IPO
| What | Day |
|---|---|
| Registration filed | Jul 17, 2026 |
| Exchange registration filed | Aug 4, 2026 |
| Declared effective by the SEC | Aug 6, 2026 |
| Priced | Aug 6, 2026 |
| First trade | Aug 7, 2026 |
| Lock-up ends | Feb 2, 2027 |
How did its first days trade?
From its daily bars, each close against its $16 offer price.
| Day | Open | Close | From the offer |
|---|---|---|---|
| Aug 7 | $15.75 | $16 | 0.0% |
| Aug 10 | $16.50 | $15.99 | -0.1% |
| Aug 11 | $16.39 | $16.52 | +3.2% |
| Aug 12 | $16.52 | $16.24 | +1.5% |
| Aug 13 | $16.32 | $16.35 | +2.2% |
The other IPOs expected
| Company | Price |
|---|---|
| $19 to $21 | |
| $15 to $17 | |
| $15 to $17 | |
| $7 | |
| $5 to $7 |
BlossomHill Therapeutics IPO questions
When is BlossomHill Therapeutics' IPO?
Listed Aug 7, 2026 at $16 on Nasdaq as BLSM.
What is BlossomHill Therapeutics' IPO price?
BlossomHill Therapeutics' IPO priced at $16 a share, per its final prospectus of Aug 7, 2026.
How many shares is BlossomHill Therapeutics selling?
9,375,000 shares, and the underwriters may buy 1,406,250 more, per its final prospectus (424B4).
Who are the underwriters?
J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, and H.C. Wainwright, as the prospectus's cover names them.
When does the lock-up end?
BlossomHill Therapeutics' IPO lock-up ends Feb 2, 2027. Its final prospectus says: “.”
Does Breakaway rate BlossomHill Therapeutics?
Breakaway scores a new stock from its second trading day, ranked against every US stock it scores. For its first 21 sessions the page says New listing in place of the tier, and each check that needs more history waits for it.
Can Breakaway say where BlossomHill Therapeutics' price will go?
No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Every new listing, ranked live, free. No account.
See all 16 new listings rankedSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.